Results 101 to 110 of about 20,887 (223)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Oncotarget, 2018
[This corrects the article DOI: 10.18632/oncotarget.24859.].
Agarwal, Saurabh, Milazzo, Giorgio, Rajapakshe, Kimal, Bernardi, Ronald, Chen, Zaowen, Eveline, Barbieri, Koster, Jan, Perini, Giovanni, Coarfa, Cristian, Shohet, Jason M.   +9 more
openaire   +2 more sources

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

Cancer Cell International, 2017
Background MYCN gene amplification is related to risk stratification. Therefore it is important to identify accurately the level of the MYCN gene as early as possible in neuroblastoma (NB); however, for patients with bone marrow (BM) metastasis who need ...
Zhi-Xia Yue, Cheng Huang, Chao Gao, Tian-Yu Xing, Shu-Guang Liu, Xing-Jun Li, Qian Zhao, Xi-Si Wang, Wen Zhao, Mei Jin, Xiao-Li Ma   +10 more
doaj   +1 more source

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood.
Mariona Morell‐Daniel, Santiago Pérez‐Hoyos, Aroa Soriano, Ana Coma, Amalia Varo, Raquel Hladun, Gabriela Guillén, Soraya Mico, Marta Garrido, Lourdes Rubio, Alba Rubio‐San‐Simón, Ana Minguez, Ricardo López‐Almaraz, Laura Illade, Miguel F. Segura, Lucas Moreno   +15 more
wiley   +1 more source

Regulatory effect of C12ORF66 on viability of MYCN amplified high-risk neuroblastoma cells [PDF]

Jichu yixue yu linchuang
Objective To explore the effect of open reading frame 66 (C12ORF66) located at chromosome 12 on the viability of MYCN amplified NB cell lines. Methods DDatasets GSE16476 and GSE49710 in R2 database were analyzed for expression level of C12ORF66 in MYCN
JIA Anna, ZHAN Shijia, ZHANG Xuan, GUO Jinxin, YU Yongbo, GUO Yongli, CHANG Yan
doaj   +1 more source

TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Enzalutamide‐mediated AR suppression induces TMEM59L during prostate cancer progression. TMEM59L interacts with MUC1 and promotes its nuclear enrichment. Nuclear MUC1 activates β‐catenin/TCF4‐dependent MYC signalling, driving neuroendocrine differentiation, stemness and EMT.
Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu   +7 more
wiley   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma

Communications Biology
Retinoblastoma are childhood eye tumors arising from retinal precursor cells. Two distinct retinoblastoma subtypes with different clinical behavior have been described based on gene expression and methylation profiling.
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T. W. Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hanenberg, Sven Rahmann, Dietmar R. Lohmann, Alexander Schramm, Petra Ketteler   +19 more
doaj   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

MYCN Gene Copy Number Status Detected by FISH Method and Its Correlation with Outcome and Clinicopathological Variables in Childhood Neuroblastoma [PDF]

Middle East Journal of Cancer
Background: Neuroblastoma is the most common extracranial solid tumor in children. MYCN gene amplification (MNA) is an independent prognostic factor for rapid tumor progression and poor prognosis, regardless of age and clinical stage.
Mahdi Shahriari, Akbar Safaei, Parvaneh Davoudi, Bozorgmehr Hedayati   +3 more
doaj   +1 more source

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K, Pritam Kumar Roy, Maniklal Shee, Budhaditya Mukherjee, Aoife Ward Gahlawat, Mahitosh Mandal   +5 more
wiley   +1 more source